⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL5035760 | 1.00 | HIF1A (0.36) | — | |
| Piperazine SCHEMBL5700791 | 0.96 | HIF1A (0.43) | — | |
| Piperazine SCHEMBL29088716 | 0.96 | HIF1A (0.43) | — | |
| Pyrrolidine SCHEMBL27735935 | 0.90 | ALDH1A1 (0.47) | — | |
| Piperazine SCHEMBL16008573 | 0.89 | HIF1A (0.43) | — | |
| Phosphoric Acid SCHEMBL11120031 | 0.84 | HIF1A (0.42) | — | |
| Phosphoric Acid SCHEMBL1652119 | 0.84 | — | — | |
| Phosphoramidic Acid SCHEMBL28845463 | 0.83 | — | — | |
| Thiomorpholine SCHEMBL28543864 | 0.83 | FDPS (0.33) | — | |
| Morpholine SCHEMBL412425 | 0.83 | MEN1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | claimed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | claimed |
| US-20220162153-A1 | Process for Making Levoamphetamine | Pharmapotheca A, Inc. | 2022-05-26 | — | — | US | claimed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | claimed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | claimed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | claimed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | claimed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | claimed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | claimed |
| WO-2015130661-A1 | SYNTHESIS OF CHIRAL AMPHETAMINE DERIVATIVES BY STEREOSPECIFIC, REGIOSELECTIVE CUPRATE ADDITION REACTION WITH AZIRIDINE PHOSPHORAMIDATE COMPOUNDS | CHEMAPOTHECA, LLC (US) | 2015-09-03 | — | — | WO | claimed |
| WO-2015130660-A1 | SYNTHESIS OF RACEMIC AMPHETAMINE DERIVATIVES BY CUPRATE ADDITION REACTION WITH AZIRIDINE PHOSPHORAMIDATE COMPOUNDS | CHEMAPOTHECA, LLC (US) | 2015-09-03 | — | — | WO | claimed |
| US-20150183716-A1 | Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds | CHEMAPOTHECA, LLC (US) | 2015-07-02 | — | — | US | claimed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20150183716-A1 | Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds | CHEMAPOTHECA, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183716-A1 | Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds | CHEMAPOTHECA, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |